Liraglutide, GLP-1 receptor agonist, for chronic weight loss
- 11 August 2016
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 11 (5) , 373-378
Abstract
Introduction: Since 1990, the prevalence of obesity has been steadily increasing in the United States. Over the past four years, new medications have become approved and available, allowing for more options in the management of chronic weight loss among overweight or obese patients. This review article summarizes the efficacy, safety, and clinical attributes of liraglutide among overweight or obese patients with or without comorbidities. Areas covered: A MEDLINE search, from 1970 to June 2016, was conducted using key terms—glucagon-like peptide-1 receptor agonist, liraglutide, overweight, and obesity. Published clinical trials, in the English-language and with primary endpoints related to weight loss, were reviewed and critiqued in this article. Expert commentary: Available as a subcutaneous daily injection, liraglutide is the first glucagon-like peptide-1 (GLP-1) receptor agonist indicated for obesity management, as adjunct therapy with lifestyle and behavioral modifications. Liraglutide 3 mg daily has been associated with greater weight loss than placebo or orlistat in patients without type 2 diabetes. Additionally, liraglutide has resulted in reductions in waist circumference, systolic and diastolic blood pressure, and improvements in lipid panel among overweight and obese patients with and without type 2 diabetes.Keywords
This publication has 22 references indexed in Scilit:
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in AdultsJACC, 2014
- An overview of the pharmacokinetics, efficacy and safety of liraglutideDiabetes Research and Clinical Practice, 2012
- Influence of hepatic impairment on pharmacokinetics of the human GLP‐1 analogue, liraglutideBritish Journal of Clinical Pharmacology, 2010
- Effect of renal impairment on the pharmacokinetics of the GLP‐1 analogue liraglutideBritish Journal of Clinical Pharmacology, 2009
- A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitusClinical Therapeutics, 2009
- Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes MellitusAnnals of Pharmacotherapy, 2009
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 DiabetesDiabetes Care, 2009
- Retinal Arteriolar Narrowing Predicts Incidence of DiabetesDiabetes, 2008
- Comment on: Lachin et al. (2007) The Hemoglobin Glycation Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control and Complications Trial: Diabetes 56:1913–1921, 2007Diabetes, 2008
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006